Clinical trials: Atrial Fibrillation
Atrial Fibrillation
SPARK: Safety Study of Pradaxa in Atrial Fibrillation Patients by Regulatory Requirement of Korea
This is a prospective, non-interventional, open-label, multi-centre study. It will provide additional safety information of Pradaxa in Korean patients with non-valvular AF in clinical settings.
- Trial name
- NCT01774370
- Testing
- Pradaxa (Dabigatran etexilate mesilate)
- Where
- South Korea
- Volunteers
- 3,182 people
- Sponsor
- Boehringer Ingelheim
Atrial Fibrillation
Intravenous Cardioversion of Atrial Fibrillation (AF) With AZD1305
This study is being carried out to see which dose of AZD1305 is safe and effective in cardioverting atrial fibrillation into normal heart rhythm.
- Trial name
- NCT00915356
- Testing
- AZD1305
- Where
- 31 sites in Czechia, Denmark and 6 more
- Volunteers
- 228 people
- Sponsor
- AstraZeneca
Persistent Atrial Fibrillation
Feasibility Study of the FARAPULSE™ Cardiac Ablation System Plus in the Treatment of Persistent Atrial Fibrillation(PersAFOne II)
The objective of this safety and feasibility study is to assess whether the endocardial creation of electrically nonconductive lesions via PEF catheter ablation applied using the FARAPULSE Cardiac Ablation System Plus is a…
- Trial name
- PersAFOne II (NCT05152966)
- Testing
- Ablation
- Where
- Czechia
- Volunteers
- 20 people
- Sponsor
- Boston Scientific Corporation
Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation
Automated Assessment of PVI Using a Novel EP Recording System
A prospective, multi-center study with the CathVision Cube® system and the PVI Analyzer software in radiofrequency (RF), cryo-balloon (CB), and Pulse Field Ablation (PFA) procedures.
- Trial name
- PVISION (NCT05043883)
- Testing
- CathVision Cube® system
- Where
- 4 sites in Belgium, France
- Volunteers
- 101 people
- Sponsor
- CathVision ApS
Atrial Fibrillation, Hemorrhage
Management of Major Bleeding Events in Atrial Fibrillation Patients Using Pradaxa
This study is being conducted to collect data on the management of major bleeding events occurring in patients with atrial fibrillation taking dabigatran etexilate.
- Trial name
- NCT02149303
- Testing
- Dabigatran 75 mg, Dabigatran 150 mg
- Where
- 5 sites in United States
- Volunteers
- 191 people
- Sponsor
- Boehringer Ingelheim
Paroxysmal Atrial Fibrillation
LSI (Lesion Index) Workflow Observational Study
This clinical study is a prospective, multicenter, post-market, single-arm, observational study designed to characterize the usage of the Lesion Index (LSI) with the market-released TactiCath Contact Force Ablation Catheter…
- Trial name
- NCT03906461
- Testing
- Radiofrequency Ablation
- Where
- 9 sites in United States, Germany and 3 more
- Volunteers
- 143 people
- Sponsor
- Abbott Medical Devices
Atrial Fibrillation, Congestive Heart Failure
Investigational Device Exemption (IDE) Study for the Approval of Closed Loop Stimulation (CLS) and Cardiac Resyncronization Pacing Therapies (CRT) for the Treatment of Atrial Fibrillation (AF) With Ablate and Pace
The purpose of this study is to demonstrate the safety and effectiveness of biventricular pacing over conventional right ventricular pacing in patients with persistent or permanent, symptomatic atrial fibrillation undergoing…
- Trial name
- AVAIL (NCT00356057)
- Testing
- Protos DR/CLS and Stratos LV CRT pacemakers
- Where
- 10 sites in United States
- Volunteers
- 153 people
- Sponsor
- Biotronik, Inc.
Atrial Fibrillation
Mapping Electrogram Morphology Recurrence for Atrial Fibrillation Ablation
The overall goal of this project is to test the feasibility of performing real-time electrogram morphology recurrence (EMR) mapping in patients with persistent atrial fibrillation (AF) to locate areas of high electrogram…
- Trial name
- NCT03082963
- Testing
- Electrogram Morphology Mapping (EMR)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Jeffrey Goldberger
Atrial Fibrillation
mHealth Screening to Prevent Strokes
The purpose of this study is to investigate whether it is possible to identify a high-risk cohort suitable for screening for asymptomatic atrial fibrillation using claims data, and then engage those individuals in a mobile health…
- Trial name
- mSToPS (NCT02506244)
- Testing
- iRhythm ZIO XT Patch, Wristband by Amiigo
- Where
- United States
- Volunteers
- 6,135 people
- Sponsor
- Scripps Translational Science Institute
Primary Disease
Dabigatran Versus Warfarin After Mitral and/or Aortic Bioprosthesis Replacement and Atrial Fibrillation Postoperatively
DAWA is a phase 2, prospective, open-label, randomized, pilot study. The main variable to be observed in this study is intracardiac thrombus.
- Trial name
- DAWA (NCT01868243)
- Testing
- Dabigatran, Warfarin
- Where
- Brazil
- Volunteers
- 27 people
- Sponsor
- Hospital Ana Nery
Atrial Fibrillation
Ranolazine for the Prevention of Atrial Fibrillation After Electrical Cardioversion
The investigators hypothesize that ranolazine would decrease the incidence of recurrence of Atrial Fibrillation (AF) after electrical cardioversion of persistent AF.
- Trial name
- GILEAD (NCT01349491)
- Testing
- Ranolazine
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- University of Oklahoma
Scar-related Atrial Tachycardia, Paroxysmal Atrial Fibrillation
A Study Assessing Arrhythmia Mapping With the Multi-Electrode OPTRELL™ Mapping Catheter
The purpose of this study is to assess the performance and safety for the use of the OPTRELL Catheter for intracardiac mapping in the atria and ventricles.
- Conditions
- Scar-related Atrial Tachycardia, Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation, Tachycardia, Ventricular
- Trial name
- OPTIMUM (NCT04983797)
- Testing
- OPTRELL Mapping Catheter
- Where
- 3 sites in Belgium, Lithuania
- Volunteers
- 31 people
- Sponsor
- Biosense Webster, Inc.
Atrial Fibrillation
A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF)
This study will evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of one or more doses of AP30663 for cardioversion in adult participants with AF.
- Trial name
- NCT04571385
- Testing
- AP30663
- Where
- 15 sites in Denmark, Hungary
- Volunteers
- 66 people
- Sponsor
- Acesion Pharma
Atrial Fibrillation
SMART-SF Radiofrequency Ablation Safety Study
This is a prospective safety assessment of the study device during radiofrequency (RF) ablation treatment of patients with drug refractory symptomatic atrial fibrillation (SMART-SF).
- Trial name
- NCT02359890
- Testing
- THERMOCOOL® SMARTTOUCH® (RF ablation treatment)
- Volunteers
- 165 people
- Sponsor
- Biosense Webster, Inc.
Patients With Atrial Fibrillation at Risk for Thrombus Formation, Thromboembolism, Stroke
Registry on WATCHMAN Outcomes in Real-Life Utilization
The WATCHMAN LAA Closure Technology is designed to prevent embolization of thrombi that may form in the LAA, thereby preventing the occurrence of ischemic stroke and systemic thromboembolism.
- Trial name
- EWOLUTION (NCT01972282)
- Testing
- WATCHMAN Left Atrial Appendage Closure
- Where
- 47 sites in Belgium, France and 11 more
- Volunteers
- 1,025 people
- Sponsor
- Boston Scientific Corporation